Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chugai To Market, Test Tarceva In Japan As Iressa Alternative (Japan)

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical of Japan plans to launch Tarceva (erlotinib hydrochloride) for treating non-small cell lung cancer by the end of the year. Chugai's Swiss parent, Roche, sells the drug elsewhere and Chugai plans to begin Phase II clinical trials on the drug for treating pancreatic cancer, an indication already approved elsewhere. Chugai expects healthy sales in Japan because of problems AstraZeneca had with its similar drug, Iressa (gefitinib). (Click here for more - may require paid subscription

You may also be interested in...

Monoclonal Antibodies For COVID-19: Cocktails Present Efficacy, Manufacturing Tradeoffs

Ability to quickly scale manufacturing is a key criteria for Operation Warp Speed therapeutics, but for monoclonal antibodies the most effective approach may mean fewer doses. FDA’s Janet Woodcock said the government is supporting a range of antibody approaches for COVID-19 so that if virus escape mutants emerge from single antibody treatment there will be other options, while Regeneron argues the cocktail approach is safer, even though it will likely mean fewer doses of drug will be available.

QUOTED. 16 July 2020. Martin Walger.

German sickness insurance funds are under unusual financial pressure as a result of the COVID-19 pandemic. And a recent decision to reduce reimbursement for COVID-19 confirmatory tests by one third has left testing labs and diagnostics makers frustrated. See what Martin Walger, chief executive of the German diagnostic industry association (VDGH) said about it here.

Priority Review Voucher Eligibility List Gains Three Tropical Diseases

US FDA adds brucellosis, opisthorchiasis and paragonimiasis to the list of qualifying diseases but declines to include clonorchiasis and coccidioidomycosis, finding a significant market in developed nations for treatments or vaccines addressing the two conditions.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts